In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

while in May it hooked up with Goldfinch Bio on a kidney disease project. Since the start of the year Gilead has also partnered with Insitro and Yuhan Corp on liver diseases.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and led to more ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir. The Indian ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile, the ...

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

-- Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets -- -- Gilead Receives Exclusive Rights to Develop and Commercialize ...

Gilead Sciences rose 2% in early trading, after the biotech reported positive data for a long-acting HIV prevention drug that promises to be a big seller. The drug, called lenacapavir, was 96% ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...